Literature DB >> 18767131

Decitabine as "bridge therapy" to a MUD transplant in relapsed AML postautologous stem cell transplantation.

Celalettin Ustun, Abhishek Kalla, Stephanie Farrow, David L DeRemer, Anand Jillella.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18767131     DOI： 10.1002/ajh.21267

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  4 in total

1.  Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.

Authors:  Armin Rashidi; Maryam Ebadi; Graham A Colditz; John F DiPersio
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-31       Impact factor: 5.742

Review 2.  Decitabine: a review of its use in older patients with acute myeloid leukaemia.

Authors:  Monique P Curran
Journal:  Drugs Aging       Date:  2013-06       Impact factor: 3.923

Review 3.  Bridging Strategies to Allogeneic Transplant for Older AML Patients.

Authors:  Judith Hecker; Isabella Miller; Katharina S Götze; Mareike Verbeek
Journal:  Cancers (Basel)       Date:  2018-07-11       Impact factor: 6.639

4.  Low-dose hypomethylating agent decitabine in combination with aclacinomycin and cytarabine achieves a better outcome than standard FLAG chemotherapy in refractory/relapsed acute myeloid leukemia patients with poor-risk cytogenetics and mutations.

Authors:  Limin Li; Xiaoqian Zhang; Hongjuan Yu; Mingwen Zhang; Mengyuan Xu; Jie Liu; Yueyue Fu; Hongbin Meng; Chengfang Lyu; Xiaoxia Li; Jin Zhou
Journal:  Onco Targets Ther       Date:  2018-10-12       Impact factor: 4.147
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.